(E)-3-[4-[4-(dimethylamino)-3-ethylphenyl]-4,5,6,7-tetrahydro-1-benzofuran-2-yl]prop-2-enoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (E)-3-[4-[4-(dimethylamino)-3-ethylphenyl]-4,5,6,7-tetrahydro-1-benzofuran-2-yl]prop-2-enoic acid
• 化学式: C₂₁H₂₅NO₃
• 分子量: 339.4
• InChiKey: HDQSWVBYXNXWDH-PKNBQFBNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  53.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Selective rxr ligands
  申请人：——

  公开号：US20040198980A1

  公开（公告）日：2004-10-07

  The present invention includes novel retinoid compounds that have selectivity as RXR agonists on one or more isoforms of RXR, currently, RXR&agr;, RXR&bgr;, or RXR&ggr;. The present compounds, and pharmaceutical compositions incorporating these compounds, therefore, are effective in treating conditions mediated by RXRs. Among other physiological responses, the compounds of the present invention reduce blood glucose and maintain body weight, and, thus, are useful for the treatment of diabetes (NIDDIM) and obesity.

  本发明涵盖了新型视黄醇化合物，其在RXR的一个或多个亚型上具有选择性作为RXR激动剂，目前包括RXRα、RXRβ或RXRγ。因此，本化合物及包含这些化合物的药物组合物在治疗由RXR介导的疾病方面是有效的。除其他生理反应外，本发明的化合物可降低血糖并维持体重，因此对于治疗糖尿病（NIDDIM）和肥胖症是有用的。
• SELECTIVE RXR LIGANDS
  申请人：HAFFNER Dale Curt

  公开号：US20070099991A1

  公开（公告）日：2007-05-03

  The present invention includes novel retinoid compounds that have selectivity as RXR agonists on one or more isoforms of RXR, currently, RXRα, RXRβ, or RXRγ. The present compounds, and pharmaceutical compositions incorporating these compounds, therefore, are effective in treating conditions mediated by RXRs. Among other physiological responses, the compounds of the present invention reduce blood glucose and maintain body weight, and, thus, are useful for the treatment of diabetes (NIDDIM) and obesity.

  本发明包括新型视黄醇类化合物，其具有对RXRα、RXRβ或RXRγ中一种或多种同工型具有选择性的RXR激动剂。因此，本化合物及包含这些化合物的制药组合物在治疗由RXR介导的疾病方面是有效的。除了其他生理反应外，本发明的化合物可以降低血糖并维持体重，因此，对于治疗糖尿病（NIDDIM）和肥胖症是有用的。
• BICYCLIC HETEROCYCLES AS RXR LIGANDS
  申请人：SmithKline Beecham Corporation

  公开号：EP1430042A2

  公开（公告）日：2004-06-23
• US7173134B2
  申请人：——

  公开号：US7173134B2

  公开（公告）日：2007-02-06
• [EN] SELECTIVE RXR LIGANDS<br/>[FR] LIGANDS SELECTIFS DU RECEPTEUR X RETINOIDE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2003027090A2

  公开（公告）日：2003-04-03

  The present invention includes novel retinoid compounds that have selectivity as RXR agonists on one or more isoforms of RXR, currently, RXRα RXRβ, or RXRϜ. The present compounds, an d ph armaceutical compositions incorporating these compounds, therefore, are effective in treating conditions mediated by RXRs. Among other physiological responses, the compounds of the present invention reduce blood glucose and maintain body weight, and, thus, are useful for the treatment of diabetes (NIDDIM) and obesity